Showing 511-520 of 4344 results for "".
Ask an Expert: What is the Role of Dermatology Hospitalists?
https://practicaldermatology.com/topics/general-topics/ask-an-expert-april-2019/19599/Helena Pasieka, MD, MS talks to host Adam Friedman, MD about the important role dermatologists can play in supporting patient care in the hospital setting. Consulting dermatologists in the hospital setting change the diagnosis up to 50% of the time!What's the Best Approach to Lichen Planus?
https://practicaldermatology.com/topics/general-topics/what-s-the-best-approach-to-lichen-planus/18286/Lichen planus doesn't garner much attention in therapeutic discussions, perhaps because it is so challenging to treat. Kevin Wang, MD, PhD talks to host Adam Friedman, MD about the challenges of managing the disease and his approach to patient care.Update on Pediatric Vulvar Lichen Sclerosis
https://practicaldermatology.com/topics/general-topics/update-on-pediatric-vulvar-lichen-sclerosis/18733/Pediatric vulvar lichen sclerosis may be under-recognized. Pediatric dermatologist Kalyan Marathe, MD talks to host Adam Friedman, MD about the importance of identifying and treating the condition, providing relief to patients and potentially avoiding unnecessary testing.Vehicle Innovations: Experts Discuss What's New
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/vehicle-innovations-experts-discuss-what-s-new/18915/Peter Lio, MD and Elaine Siegfried, MD discuss recent innovations in the science behind new vehicles and how these innovations improve treatment, as well as what may hinder some patients' access to these new vehicles. They also offer tips on treatment action plans for atopic patients.DermWireTV: SPF Accuracy, Dupixent PN Data, AD Pipeline
https://practicaldermatology.com/topics/skin-cancer-photoprotection/dermwiretv-spf-accuracy-dupixent-pn-data-ad-pipeline/20009/Researchers from the Environmental Working Group say that many sunscreens offer less than half their stated SPF protection against UVB. The Thriving in Aesthetics educational series featuring Sabrina Fabi, MD and Steven Dayan, MD is returning with a focus on diversity in aesthetics. As eczema awareDermWireTV: AAD VMX Highlights, Upneeq Launches for Ptosis
https://practicaldermatology.com/topics/practice-management/dermwiretv-aad-vmx-highlights-upneeq-launches-for-ptosis/19931/The American Academy of Dermatology's VMX format delivers updates on a range of hot topics in dermatology, including an update on the COVID-19 dermatology vaccine registry from Esther Freeman, MD and teledermatology from Jules Lipoff, MD. Upneeq, a newly launched oxymetazoline eyedrop from RVL pharmAn Excellent Networking Opportunity: DERM2021
https://practicaldermatology.com/series/dermatology-education-foundation/an-excellent-networking-opportunity-derm2021/19963/From opportunities to connect and network with other NPs and PAs to going to sessions presented by some of her favorite dermatologists, such as Ted Rosen, MD, to learn about what’s in the pipeline and coming to market soon, Leigh Ann Pansch, MSN, FNP-BC, DCNP is excited to attend the DERM2021 NP/PAAssessing the Aging Face
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/assessing-the-aging-face/18849/Jason Emer, MD discusses the evolving filler market and new trends in facial rejuvenation treatments. He offers tips for assessing patients globally—in three and four dimensions—in order to choose the right options for contouring the face with fillers and fat in order to give patients the most naturHad Your Fill?
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/had-your-fill/18531/If the US filler market seems robust, you should see what's available outside the US, says Hassan Galadari, MD. He provides a global perspective on fillers with a focus on up-and-coming products, the importance of understanding anatomy, and advances in recognizing and treating complications.The Complex World of Biosimilars
https://practicaldermatology.com/topics/psoriasis/the-complex-world-of-biosimilars/18633/Jashin Wu, MD, discusses potential concerns with biosimilars, including the chance of inducing variable immunogenic responses compared with reference agents. Although there are currently no biosimilars approved for use in psoriasis in the United States, these agents are fast approaching market avail